Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in CKD: translational opportunities and challenges.

Zoccali, Carmine; Ortiz, Alberto; Blumbyte, Inga Arune; Rudolf, Sarina; Beck-Sickinger, Annette G; Malyszko, Jolanta; Spasovski, Goce; Carriazo, Sol; Viggiano, Davide; Kurganaite, Justina; Sarkeviciene, Vaiva; Rastenyte, Daiva; Figurek, Andreja; Rroji, Merita; Mayer, Christopher; Arici, Mustapha; Martino, Gianvito; Tedeschi, Gioacchino; Bruchfeld, Annette; Spoto, Belinda; ... (2021). Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in CKD: translational opportunities and challenges. Nephrology, dialysis, transplantation, 37(Supplement_2), ii14-ii23. Oxford University Press 10.1093/ndt/gfab284

Preview

Text gfab284.pdf - Published Version Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC). Download (983kB) | Preview

Neuropeptide Y (NPY) is a 36-amino-acid peptide member of a family also including peptide YY and pancreatic polypeptide which are all ligands to Gi/Go coupled receptors. NPY regulates several fundamental biologic functions including appetite/satiety, sex and reproduction, learning and memory, cardiovascular and renal function and the immune function. The mesenteric circulation is a major source of NPY in the blood in man and this peptide is considered a key regulator of the gut-brain cross-talk. A progressive rise in circulating NPY accompanies the progression of CKD toward kidney failure and NPY robustly predicts cardiovascular events in this population. Furthermore, NPY is suspected as a possible player in the accelerated cognitive function decline and dementia in patients with CKD and in dialysis patients. In theory, Interfering with the NPY system has relevant potential for the treatment of diverse diseases from cardiovascular and renal diseases to diseases of the central nervous system. Pharmaceutical formulations for effective drug delivery and cost as well as the complexity of diseases potentially addressable by NPY/NPY antagonists have been a problem until now. This in part explains the slow progress of knowledge about the NPY system in the clinical arena. There is now a renewed research interest on the NPY system in psycho pharmacology and in pharmacology in general and new studies and a new breed of clinical trials may eventually bring the expected benefits in human health by drugs interfering with this system.

Interest & Impact

Downloads

111 since deposited on 15 Dec 2021
31 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item